Indirect comparison of three PARP inhibitors (olaparib, niraparib, and rucaparib) as maintenance treatment in ovarian carcinoma patients responding to platinum therapy.

IF 0.9 4区医学 Q4 PHARMACOLOGY & PHARMACY

International journal of clinical pharmacology and therapeutics Pub Date : 2022-06-02 DOI:10.5414/CP204243

D. Mengato, L. Cancanelli, L. Di Spazio, M. Rivano, M. Chiumente, A. Messori

引用次数: 2

查看原文本刊更多论文

间接比较三种PARP抑制剂(奥拉帕尼、尼拉帕尼和鲁卡帕尼)作为维持治疗对铂治疗有反应的卵巢癌患者的疗效。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文求助全文

来源期刊

International journal of clinical pharmacology and therapeutics 医学-药学

CiteScore

1.70

自引率

12.50%

发文量

116

审稿时长

4-8 weeks

期刊介绍： The International Journal of Clinical Pharmacology and Therapeutics appears monthly and publishes manuscripts containing original material with emphasis on the following topics: Clinical trials, Pharmacoepidemiology - Pharmacovigilance, Pharmacodynamics, Drug disposition and Pharmacokinetics, Quality assurance, Pharmacogenetics, Biotechnological drugs such as cytokines and recombinant antibiotics. Case reports on adverse reactions are also of interest.